Tags

Type your tag names separated by a space and hit enter

Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel.
MMWR Morb Mortal Wkly Rep. 2018 Nov 02; 67(43):1216-1220.MM

Abstract

Postexposure prophylaxis (PEP) with hepatitis A (HepA) vaccine or immune globulin (IG) effectively prevents infection with hepatitis A virus (HAV) when administered within 2 weeks of exposure. Preexposure prophylaxis against HAV infection through the administration of HepA vaccine or IG provides protection for unvaccinated persons traveling to or working in countries that have high or intermediate HAV endemicity. The Advisory Committee on Immunization Practices (ACIP) Hepatitis Vaccines Work Group conducted a systematic review of the evidence for administering vaccine for PEP to persons aged >40 years and reviewed the HepA vaccine efficacy and safety in infants and the benefits of protection against HAV before international travel. The February 21, 2018, ACIP recommendations update and supersede previous ACIP recommendations for HepA vaccine for PEP and for international travel. Current recommendations include that HepA vaccine should be administered to all persons aged ≥12 months for PEP. In addition to HepA vaccine, IG may be administered to persons aged >40 years depending on the provider's risk assessment. ACIP also recommended that HepA vaccine be administered to infants aged 6-11 months traveling outside the United States when protection against HAV is recommended. The travel-related dose for infants aged 6-11 months should not be counted toward the routine 2-dose series. The dosage of IG has been updated where applicable (0.1 mL/kg). HepA vaccine for PEP provides advantages over IG, including induction of active immunity, longer duration of protection, ease of administration, and greater acceptability and availability.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

30383742

Citation

Nelson, Noele P., et al. "Update: Recommendations of the Advisory Committee On Immunization Practices for Use of Hepatitis a Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel." MMWR. Morbidity and Mortality Weekly Report, vol. 67, no. 43, 2018, pp. 1216-1220.
Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep. 2018;67(43):1216-1220.
Nelson, N. P., Link-Gelles, R., Hofmeister, M. G., Romero, J. R., Moore, K. L., Ward, J. W., & Schillie, S. F. (2018). Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR. Morbidity and Mortality Weekly Report, 67(43), 1216-1220. https://doi.org/10.15585/mmwr.mm6743a5
Nelson NP, et al. Update: Recommendations of the Advisory Committee On Immunization Practices for Use of Hepatitis a Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep. 2018 Nov 2;67(43):1216-1220. PubMed PMID: 30383742.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. AU - Nelson,Noele P, AU - Link-Gelles,Ruth, AU - Hofmeister,Megan G, AU - Romero,José R, AU - Moore,Kelly L, AU - Ward,John W, AU - Schillie,Sarah F, Y1 - 2018/11/02/ PY - 2018/11/2/entrez PY - 2018/11/2/pubmed PY - 2018/11/6/medline SP - 1216 EP - 1220 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb. Mortal. Wkly. Rep. VL - 67 IS - 43 N2 - Postexposure prophylaxis (PEP) with hepatitis A (HepA) vaccine or immune globulin (IG) effectively prevents infection with hepatitis A virus (HAV) when administered within 2 weeks of exposure. Preexposure prophylaxis against HAV infection through the administration of HepA vaccine or IG provides protection for unvaccinated persons traveling to or working in countries that have high or intermediate HAV endemicity. The Advisory Committee on Immunization Practices (ACIP) Hepatitis Vaccines Work Group conducted a systematic review of the evidence for administering vaccine for PEP to persons aged >40 years and reviewed the HepA vaccine efficacy and safety in infants and the benefits of protection against HAV before international travel. The February 21, 2018, ACIP recommendations update and supersede previous ACIP recommendations for HepA vaccine for PEP and for international travel. Current recommendations include that HepA vaccine should be administered to all persons aged ≥12 months for PEP. In addition to HepA vaccine, IG may be administered to persons aged >40 years depending on the provider's risk assessment. ACIP also recommended that HepA vaccine be administered to infants aged 6-11 months traveling outside the United States when protection against HAV is recommended. The travel-related dose for infants aged 6-11 months should not be counted toward the routine 2-dose series. The dosage of IG has been updated where applicable (0.1 mL/kg). HepA vaccine for PEP provides advantages over IG, including induction of active immunity, longer duration of protection, ease of administration, and greater acceptability and availability. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/30383742/full_citation L2 - https://doi.org/10.15585/mmwr.mm6743a5 DB - PRIME DP - Unbound Medicine ER -